Education
About Us
Working with TipRanks
Follow Us
D.Western Therapeutics Institute, Inc. (DE:6DW)
FRANKFURT:6DW
Total Valuation
D.Western Therapeutics Institute has a market cap or net worth of €34.62M. The enterprise value is €15.99B.
Market Cap€34.62M
Enterprise Value€15.99B
Share Statistics
D.Western Therapeutics Institute has 45,741,512 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding45,741,512
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
D.Western Therapeutics Institute’s return on equity (ROE) is -1.76 and return on invested capital (ROIC) is -77.84%.
Return on Equity (ROE)-1.76
Return on Assets (ROA)-0.77
Return on Invested Capital (ROIC)-77.84%
Return on Capital Employed (ROCE)-0.79
Revenue Per Employee22.46M
Profits Per Employee-61.44M
Employee Count21
Asset Turnover0.28
Inventory Turnover0.46
Valuation Ratios
The current PE Ratio of D.Western Therapeutics Institute is -5.47. D.Western Therapeutics Institute’s PEG ratio is 0.00.
PE Ratio-5.47
PS Ratio0.00
PB Ratio12.24
Price to Fair Value9.62
Price to FCF97.44
Price to Operating Cash Flow97.44
PEG Ratio0.00
Income Statement
In the last 12 months, D.Western Therapeutics Institute had revenue of 471.58M and earned -1.29B in profits. Earnings per share was -36.74.
Revenue471.58M
Gross Profit424.74M
Operating Income-1.21B
Pretax Income-1.29B
Net Income-1.29B
EBITDA-1.23B
Earnings Per Share (EPS)-36.74
Cash Flow
In the last 12 months, operating cash flow was 0.00 and capital expenditures 0.00, giving a free cash flow of 0.00 billion.
Operating Cash Flow0.00
Free Cash Flow0.00
Free Cash Flow per Share0.00
Dividends & Yields
D.Western Therapeutics Institute pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-0.93
52-Week Price Change47.73%
50-Day Moving Average0.57
200-Day Moving Average0.58
Relative Strength Index (RSI)54.54
Average Volume (3m)0.00
Important Dates
D.Western Therapeutics Institute upcoming earnings date is Aug 12, 2025, TBA Not Confirmed.
Last Earnings DateMay 15, 2025
Next Earnings DateAug 12, 2025
Ex-Dividend Date―
Financial Position
D.Western Therapeutics Institute as a current ratio of 11.12, with Debt / Equity ratio of 34.46%
Current Ratio11.12
Quick Ratio10.35
Debt to Market Cap0.11
Net Debt to EBITDA0.27
Interest Coverage Ratio-232.17
Taxes
In the past 12 months, D.Western Therapeutics Institute has paid 1.59M in taxes.
Income Tax1.59M
Effective Tax Rate>-0.01
Enterprise Valuation
D.Western Therapeutics Institute EV to EBITDA ratio is -5.45, with an EV/FCF ratio of -5.15.
EV to Sales14.27
EV to EBITDA-5.45
EV to Free Cash Flow-5.15
EV to Operating Cash Flow-5.18
Balance Sheet
D.Western Therapeutics Institute has €1.13B in cash and marketable securities with ¥797.98M in debt, giving a net cash position of -€328.06M billion.
Cash & Marketable Securities€1.13B
Total Debt¥797.98M
Net Cash-€328.06M
Net Cash Per Share-€7.17
Tangible Book Value Per Share€19.63
Margins
Gross margin is 87.93%, with operating margin of -256.50%, and net profit margin of -273.61%.
Gross Margin87.93%
Operating Margin-256.50%
Pretax Margin-273.27%
Net Profit Margin-273.61%
EBITDA Margin-261.71%
EBIT Margin-272.17%
Analyst Forecast
The average price target for D.Western Therapeutics Institute is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―